Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 16/20 | 0.88 |
| ▸ | SSTR5 | P35346 | 15/20 | 0.87 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.83 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.78 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24211760 | 1.00 | SSTR2 (0.88) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL24211761 | 1.00 | SSTR2 (0.88) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL17404630 | 1.00 | SSTR2 (0.88) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL30379842 | 1.00 | SSTR2 (0.88) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL24588414 | 1.00 | SSTR2 (0.88) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL18712689 | 0.97 | SSTR2 (0.83) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL29359873 | 0.97 | SSTR5 (0.92) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL26270883 | 0.97 | SSTR5 (0.92) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL19542369 | 0.97 | SSTR2 (0.82) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL31632616 | 0.97 | SSTR2 (0.83) | SSTR2SSTR5SSTR4SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2025-10-09 | — | — | US | claimed |
| CN-119331056-A | [ Tyr3Preparation method and application of Octreotate-D-configuration oncolytic peptide conjugate and fluorescent probe thereof | 青岛大学 | 2025-01-21 | — | — | CN | claimed |
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | Clarity Pharmaceuticals Ltd (AU) | 2024-02-15 | — | — | US | claimed |
| EP-4196175-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2023-06-21 | — | — | EP | claimed |
| EP-3965751-B1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM ISOTOPE TECH MUNICH SE (DE) | 2022-12-28 | — | — | EP | claimed |
| WO-2022032353-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2022-02-17 | — | — | WO | claimed |
| CN-122074048-A | Methods of treating cancer | 诺华股份有限公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-05-12 | — | — | US | disclosed |
| WO-2026089608-A2 | RADIOPHARMACEUTICALS | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2026-04-30 | — | — | WO | disclosed |
| US-12605447-B2 | Stable formulations for radionuclide complexes | ITM SOLUCIN GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | Clarity Pharmaceuticals Ltd (AU) | 2026-03-03 | — | — | US | disclosed |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2026-01-29 | — | — | US | disclosed |
| WO-2022096103-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096673-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966211-A1 | MACROCYCLIC CHELATORS AND METHODS OF USE THEREOF | Janssen Biotech, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220072166-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2022-03-10 | — | — | US | disclosed |
| WO-2022032353-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | CA12, CLTC, CA13 | SSTR2 32/4885SSTR5 68/4885SSTR4 37/4885 |
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | GRPR, OGFR, GHRHR | SSTR2 145/4885SSTR5 55/4885SSTR4 84/4885 |
| US-12605447-B2 | Stable formulations for radionuclide complexes | EPOR, CD47, PRCP | SSTR2 15/4885SSTR5 14/4885SSTR4 42/4885 |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | FAP, SSTR1, PSMA1 | SSTR2 6/4885SSTR5 4/4885SSTR4 10/4885 |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | SSTR3, SLC43A1, SSTR1 | SSTR2 6/4885SSTR5 9/4885SSTR4 7/4885 |
| US-20220072166-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | IL15RA, IL15, SSTR5 | SSTR2 30/4885SSTR5 3/4885SSTR4 20/4885 |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | KLK3, FOLH1, PSMA1 | SSTR2 637/4885SSTR5 290/4885SSTR4 1006/4885 |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | SHBG, SLC40A1, TFRC | SSTR2 204/4885SSTR5 110/4885SSTR4 161/4885 |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR2, SSTR1, SSTR3 | SSTR2 1/4885SSTR5 5/4885SSTR4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.